IP Library › Patent Application 18968919
Patent Application
App. No. 18/968,919

ANTIDOTES TO FACTOR XA INHIBITORS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/968,919
Abstract

The present disclosure relates to antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. In one embodiment, the derivatives described herein lack or have reduced intrinsic coagulant activity.

Claims (41)

1 . A method of preventing or reducing bleeding in a subject undergoing anticoagulant therapy with a factor Xa inhibitor, comprising administering to the subject an effective amount of a two-chain polypeptide comprising the amino acid sequence of SEQ ID NO: 13 which further comprises at least one mutation, as compared to SEQ ID NO: 13, selected from the group consisting of:

(i) D12E, D29E, N59Q, N71Q, N71S, N71A, N86Q, N86S, D114E, D114S, N163S, N163Q, N259Q, N259S, and N259A,

(ii) V232I, D284M, D284Q, D284S, V308S, G311H, G311K, G311N, G311Q, and G311S, and

(iii) A290N, A290Q, A290K, H147S, H147T, H147N, H147Q, and D193N.

2 . The method of claim 1 , wherein the at least one mutation is selected from the group consisting of N86Q, N86S, D114E, and D114S.

3 . The method of claim 1 , wherein the at least one mutation is selected from the group consisting of:

i) D284M;

ii) D284M and G311S;

iii) D284M, V232I, and V308S;

iv) D284M, G311S, V232I, and V308S;

v) D284Q;

vi) D284Q and G311S;

vii) D284Q, V232I, and V308S;

viii) D284Q, G311S, V232I, and V308S;

ix) D284S and G311Q;

x) D284S, G311Q, V232I, and V308S;

xi) G311K;

xii) G311Q;

xiii) G311N;

xiv) G311S;

xv) G311H;

xvi) G311K, V232I, and V308S;

xvii) G311Q, V232I, and V308S;

xviii) G311N, V232I, and V308S;

xix) G311S, V232I, and V308S; and

xx) G311H, V232I, and V308S.

4 . The method of claim 1 , wherein the at least one mutation is selected from the group consisting of:

i) A290N;

ii) A290Q;

iii) A290K;

iv) H147S;

v) H147T;

vi) H147N;

vii) H147Q;

viii) H147S and D193N;

ix) H147T and D193N;

x) H147N and D193N; or combinations thereof.

5 . The method of claim 1 , wherein the factor Xa inhibitor is selected from the group consisting of fondaparinux, idraparinux, biotinylated idraparinux, enoxaparin, dalteparin, NAP-5, rNAPc2, DX-9065a, YM-60828, YM-150, apixaban, rivaroxaban, PD-348292, otamixaban, edoxaban, LY517717, GSK913893, razaxaban, low molecular weight heparin, betrixaban or a pharmaceutically acceptable salt thereof, and combinations thereof.

6 . The method of claim 5 , wherein the factor Xa inhibitor is selected from betrixaban, rivaroxaban, apixaban, low molecular weight heparin, and combinations thereof.

7 . The method of claim 1 , wherein the polypeptide is administered prior to a surgery.

8 . The method of claim 7 , wherein the subject is a human.